175 related articles for article (PubMed ID: 16080471)
1. Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma.
Hayashi M; Sekikawa A; Saijo A; Takada W; Yamawaki I; Ohkawa S
Anticancer Res; 2005; 25(3c):2435-8. PubMed ID: 16080471
[TBL] [Abstract][Full Text] [Related]
2. [A case of pulmonary hypertrophic osteoarthropathy associated with primary lung cancer in a young adult successfully treated with gefitinib].
Imai H; Tomizawa Y; Ishihara S; Sunaga N; Aoki H; Iijima H; Iwasaki Y; Watanabe S; Saito R; Mori M
Nihon Kokyuki Gakkai Zasshi; 2007 Feb; 45(2):189-93. PubMed ID: 17352179
[TBL] [Abstract][Full Text] [Related]
3. [A case of pulmonary pleomorphic carcinoma accompanied by pulmonary hypertrophic osteoarthropathy].
Ihara D; Hattori N; Yoshioka K; Fujitaka K; Kohno N
Nihon Kokyuki Gakkai Zasshi; 2011 Oct; 49(10):765-9. PubMed ID: 22117315
[TBL] [Abstract][Full Text] [Related]
4. Hypertrophic osteoarthropathy as a clinical manifestation of lung cancer.
Davis MC; Sherry V
Clin J Oncol Nurs; 2011 Oct; 15(5):561-3. PubMed ID: 21951743
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
6. A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor.
Abe Y; Kurita S; Ohkubo Y; Usui H; Hashizume T; Nakamura M; Ueyama Y; Fujino T
Anticancer Res; 2002; 22(6B):3485-8. PubMed ID: 12552943
[TBL] [Abstract][Full Text] [Related]
7. [Pulmonary hypertrophic osteoarthropathy associated with primary lung cancer].
Sato K; Iwasaki Y; Kobayashi G; Sunaga N; Ishihara S; Watanabe S; Tuchiya S; Saito R; Mori M
Nihon Kokyuki Gakkai Zasshi; 2000 Jan; 38(1):73-7. PubMed ID: 10723957
[TBL] [Abstract][Full Text] [Related]
8. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
10. Treatment of painful hypertrophic osteoarthropathy associated with non-small cell lung cancer with octreotide: a case report and review of the literature.
Birch E; Jenkins D; Noble S
BMJ Support Palliat Care; 2011 Sep; 1(2):189-92. PubMed ID: 24653233
[TBL] [Abstract][Full Text] [Related]
11. Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: a case report.
Ko HW; Tsai YH; Yu CT; Huang CY; Chen CH
Chang Gung Med J; 2008; 31(6):606-11. PubMed ID: 19241901
[TBL] [Abstract][Full Text] [Related]
12. [Amelioration of secondary hypertrophic osteoarthropathy following tumor resection in a patient with primary lung cancer].
Akizuki M; Homma M
Ryumachi; 1991 Jun; 31(3):311-6; discussion 316-7. PubMed ID: 1948451
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
15. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Lange T; Müller-Tidow C; Serve H; Hoffknecht P; Berdel WE; Thomas M
Oncol Rep; 2005 Dec; 14(6):1539-42. PubMed ID: 16273252
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
[TBL] [Abstract][Full Text] [Related]
17. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
18. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
20. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
